CA2970315C - Use of anti-vegf agents to treat lesions in macular degeneration patients - Google Patents

Use of anti-vegf agents to treat lesions in macular degeneration patients Download PDF

Info

Publication number
CA2970315C
CA2970315C CA2970315A CA2970315A CA2970315C CA 2970315 C CA2970315 C CA 2970315C CA 2970315 A CA2970315 A CA 2970315A CA 2970315 A CA2970315 A CA 2970315A CA 2970315 C CA2970315 C CA 2970315C
Authority
CA
Canada
Prior art keywords
vegf agent
weeks
therapy
aflibercept
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2970315A
Other languages
English (en)
French (fr)
Other versions
CA2970315A1 (en
Inventor
Oliver ZEITZ
Olaf Sowade
Haiyan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55069121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2970315(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2014/093548 external-priority patent/WO2016090590A1/en
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CA2970315A1 publication Critical patent/CA2970315A1/en
Application granted granted Critical
Publication of CA2970315C publication Critical patent/CA2970315C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2970315A 2014-12-11 2015-12-10 Use of anti-vegf agents to treat lesions in macular degeneration patients Active CA2970315C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2014/093548 WO2016090590A1 (en) 2014-12-11 2014-12-11 Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion
CNPCT/CN2014/093548 2014-12-11
CN2015089251 2015-09-09
CNPCT/CN2015/089251 2015-09-09
PCT/US2015/065022 WO2016094673A1 (en) 2014-12-11 2015-12-10 Treatment of age related macular degeneration with a small active choroidal neovascularization lesion

Publications (2)

Publication Number Publication Date
CA2970315A1 CA2970315A1 (en) 2016-06-16
CA2970315C true CA2970315C (en) 2023-08-22

Family

ID=55069121

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2970315A Active CA2970315C (en) 2014-12-11 2015-12-10 Use of anti-vegf agents to treat lesions in macular degeneration patients

Country Status (16)

Country Link
US (2) US20170326106A1 (https=)
EP (2) EP3985023A1 (https=)
JP (3) JP7320919B2 (https=)
CN (3) CN114306575A (https=)
AU (4) AU2015360496B2 (https=)
CA (1) CA2970315C (https=)
DK (1) DK3230316T3 (https=)
ES (1) ES2907148T3 (https=)
HR (1) HRP20220066T1 (https=)
HU (1) HUE057653T2 (https=)
LT (1) LT3230316T (https=)
PL (1) PL3230316T3 (https=)
PT (1) PT3230316T (https=)
RS (1) RS62827B1 (https=)
SI (1) SI3230316T1 (https=)
WO (1) WO2016094673A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PT3230316T (pt) 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
US10525035B2 (en) * 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
EP3873519A1 (en) 2018-10-29 2021-09-08 F. Hoffmann-La Roche AG Antibody formulation
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025047970A1 (ja) * 2023-08-31 2025-03-06 国立大学法人京都大学 光感受性物質含有リポタンパク質、光線力学的療法用製剤、薬物デリバリー方法及び後眼部新生血管閉塞方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69735292T2 (de) 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US8034803B2 (en) * 2001-02-06 2011-10-11 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20260004598A (ko) * 2011-01-13 2026-01-08 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
PT3230316T (pt) 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa

Also Published As

Publication number Publication date
AU2021245214B2 (en) 2024-05-02
CA2970315A1 (en) 2016-06-16
ES2907148T3 (es) 2022-04-22
CN106999511A (zh) 2017-08-01
HUE057653T2 (hu) 2022-05-28
EP3230316B1 (en) 2022-01-05
AU2015360496A1 (en) 2017-05-25
AU2021245214A1 (en) 2021-11-04
PL3230316T3 (pl) 2022-05-02
RS62827B1 (sr) 2022-02-28
US20170326106A1 (en) 2017-11-16
HRP20220066T1 (hr) 2022-04-15
LT3230316T (lt) 2022-02-10
US20190381008A1 (en) 2019-12-19
JP7320919B2 (ja) 2023-08-04
AU2024205237A1 (en) 2024-08-22
DK3230316T3 (da) 2022-03-28
EP3230316A1 (en) 2017-10-18
JP2017537117A (ja) 2017-12-14
JP2021004262A (ja) 2021-01-14
SI3230316T1 (sl) 2022-05-31
EP3985023A1 (en) 2022-04-20
AU2021107575A4 (en) 2022-01-06
CN112826934A (zh) 2021-05-25
CN114306575A (zh) 2022-04-12
PT3230316T (pt) 2022-02-24
JP2022183183A (ja) 2022-12-08
WO2016094673A1 (en) 2016-06-16
AU2015360496B2 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2021107575A4 (en) Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
Anecortave Acetate Clinical Study Group Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes
Kourlas et al. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review
Lazic et al. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration
US20040127472A1 (en) Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
HK40071471A (en) Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
HK40051590A (en) Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
KR20160013026A (ko) 폴립양 맥락막 혈관병증의 치료
WO2016090590A1 (en) Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion
HK1239535A1 (en) Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
Bhuyan et al. Comparing the Outcomes of Anti-VEGF Treatment for Choroidal Neovascular Membrane
Krader et al. Difluprednate improves results.
Ionides et al. Vitreous, Choroid, and Retina
ŞEKERYAPAN et al. Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration with Intravitreal Bevacizumab Monotherapy or Combination with Photodynamic Therapy: 12 Month Results

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201015

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251118

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251118